Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192165 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 169
- Enrollment target
NCT01192165 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 169 participants.
The verdict
NCT01192165, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Erlotinib
- DRUG Trametinib (GSK1120212)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2010-09-14 |
| Est. Completion | 2013-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192165
The ClinicalTrials.gov registry entry for NCT01192165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01192165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01192165 about?
NCT01192165 is a clinical study titled "Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel". The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, ...
What is the current status of trial NCT01192165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 169 participants. The study started on 2010-09-14. Estimated completion is 2013-10-07.
What interventions are being tested in trial NCT01192165?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Erlotinib (DRUG), Trametinib (GSK1120212) (DRUG).
Who is sponsoring clinical trial NCT01192165?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.